3rd ESTRO Forum 2015 S375 Gy=1.7). Irradiation with C12 induced a strong increase of pRb expression (2 GyE=7.7, 7 GyE=8.3). There was a minimal change of p53 expression after RT (2 Gy=1.3; 7 Gy=1.2, 2 GyE=1.6, 7 GyE=1.5). S12 cells (HPV 16 integrated) showed a decrease of pRB expression after RT with photons (2 Gy=0.47, 7 Gy=0.38). Irradiation with C12 enhanced the expression of pRb positive cells (2 GyE= 1.8,7 GyE=1.94), but showed no significant expression of p53 in the control group. W12 cells (HPV 16 episomal) showed no change of pRb expression in the control group or after RT. C12 RT induced an increase of pRb expression (2 GyE=1.5, 7 Gy=2.9). There was no significant change of p53 expression in W12 and S12 cells after RT. C12-RT showed no effect on cell cycle distribution in W12/S12 and C33A cells. 48 h after irradiation with 7 Gy photons in C33A cells and 24 h after RT in S12 cells a G2/M-block was induced.
Purpose/Objective:
Chemoradiation followed by a brachytherapeutic boost is standard of care for locally advanced cervical cancer (LACC). In the past, we implemented safely the use of neo-adjuvant chemoradiation using arc therapy. This allowed for a safe completion hysterectomy. This is a report on the long-term outcome results of this approach. Materials and Methods: Fifty-nine patients with LACC were treated (Figo IB: n=6; II: n= 41; III: n= 9; IV: n=3) between 12/2005 and 08/2014. Chemotherapy, administered in 51 patients (86%), consisted of weekly cisplatin (40mg/m2). Radiation consisted of an Intensity Modulated Arc Therapy delivered in 25 fractions. No neo-adjuvant brachytherapeutic treatment was performed. Dose prescription was: 62 Gy and 60 Gy (D med ) to the primary tumour and PET/CT-positive lymph nodes respectively; 45 Gy (minimal dose) to the uterus, cervix, upper vaginal 1/3 to ½, parametria and pelvic lymph nodes. Para-aortic irradiation was performed if N+ (n=22 or 37%).
Six weeks after the neo-adjuvant chemoradiation a hysterectomy was performed. Suspected lymph nodes at the start of the treatment were resected selectively. Radiotherapeutic and surgical feasibility and the low morbidity/toxicity rates have been published before. Results: Median FU is 33 months (3-101m). Median age at diagnosis was 56y (21-89). Pathologic complete response rate is 36% (ypT0: 36%; ypT1a: 26,4%; ypT1b: 28,8%, ypT2a1: 1,7%; ypT2b: 6,8%). Lymphnode resection was performed in 29 patients of which 6 had positive nodes. Surgical margins were free of disease in all but 2 cases (a brachytherapeutic boost was performed). Two-and 5-year local control rates are 94%. Two patients relapsed in a pelvic lymph node (2-and 5-year regional control = 96%). Two-and 5-year distant metastasis free survival is 91%. One patient developed a lung metastasis 67 months after primary diagnosis, after resection no progression was noted. Two-and 5-year disease-specific survival are both 94% and 88%. Two-and 5-year OS are 88% and 69% (4/9 death causes were not cervical cancer related). Conclusions: Neo-adjuvant chemoradiation using modern radiotherapy techniques leads to promising control and survival rates. Further research should be considered to confirm these promising data.
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Wilms tumor outcomes at a single institution treated by Children's Oncology Group (COG) protocols C. Hobbs 1 , M. Olson 2 1 Mayo Clinic, Radiation Oncology, Jacksonville Florida, USA 2 Baptist Radiation Oncology, Radiation Oncology, Jacksonville Florida, USA Purpose/Objective: Wilms tumor or nephroblastoma is the most common primary renal tumor of children, with about 500 cases per year in the United States. Treatment is individualized by tumor histology, stage, and a variety of biologic factors that help determine a patients' risk strata, and may include surgery, chemotherapy, and radiation therapy. This study sought to evaluate the outcomes for patients with Wilms tumor treated at a single institution. Materials and Methods: A retrospective review was performed of all children with Wilms tumor treated at a single institution from January 1994 through December 2012. Patients were staged by the NWTS system and managed onor per-COG protocols. Stage I and II patients were generally managed with surgery and adjuvant chemotherapy. Stage III patients were generally managed with surgery followed by adjuvant chemotherapy and flank/abdominal radiotherapy. Stage IV patients were most commonly managed with surgery, chemotherapy, and flank/lung radiotherapy. Stage V patients generally received only surgery and chemotherapy. MedCalc was utilized to develop Kaplan-Meier plots of progression free and overall survival for the population. Results: Of the 64 treated patients, there were 7 patients with recurrence (10.9%). There were no recurrences in 11 patients with stage I disease. There were 15 patients with stage II disease of which 3 patients (20%) experienced recurrence. Two patients experienced a local recurrence at 5 months and 22 months, respectively (one of these patients developed a second local recurrence 3 years after the first recurrence). One patient developed a lung metastasis 17 months after diagnosis. All recurrent stage II patients were treated and are alive with no evidence of disease (NED). Of 41 stage III patients, a recurrence was experienced in 3 patients (7%). All of these recurrences were in the lung and were experienced at 4 months, 5 months, and 7 months after diagnosis. One out of eleven patients (9%) with stage IV disease experienced a recurrence. This was a local recurrence experienced 4 months after diagnosis. None of the 8 patients with stage V disease experienced a recurrence. Risk of progression based on stage is shown in the table below. The median time to failure was 6 months from diagnosis. Of the eight total recurrences (including 2 local recurrences in a single patient), 6 were salvaged and currently have no evidence of disease. Two patients are alive with active disease. Progression-free survival was 89%. Sixty three of the 64 patients are still alive, giving an overall survival of 98.4%. The single patient who died had stage IV disease at diagnosis and experienced a recurrence prior to death. 
Stage
